Quantitative Models and Construction 1. Model Name: Hang Seng Hong Kong Innovative Drug Index (CNY) - **Model Construction Idea**: The index selects up to 50 listed companies in the Hong Kong market whose main business involves innovative drug research and development, reflecting the overall performance of innovative drug-themed listed companies in Hong Kong[37][61] - **Model Construction Process**: - **Sample Space**: Combines the sample space of the CSI Hong Kong 300 Index and the CSI Hong Kong Stock Connect Composite Index[38] - **Selection Criteria**: - Liquidity: Average daily turnover over the past year must not be less than HKD 10 million - Business Focus: Companies involved in innovative drug R&D or providing related services are selected - Market Cap: Top 50 securities by average daily market cap over the past year are included, or all securities if fewer than 50 meet the criteria - **Weighting Method**: Free-float market capitalization weighting, with individual stock weights capped at 10%[38] - **Adjustment Frequency**: Semi-annual adjustments in June and December[38] - **Model Evaluation**: The index focuses on mid-to-large innovative drug enterprises, with a high degree of industry purity, as 100% of its constituents belong to the "Pharmaceuticals and Biotechnology" secondary industry[43][44] --- Model Backtesting Results 1. Hang Seng Hong Kong Innovative Drug Index - **Annualized Return**: 8.54% (2019.1.1 - 2025.5.31)[49][50] - **Annualized Sharpe Ratio (IR)**: 0.41[49][50] - **Annualized Volatility**: 35.93%[49][50] - **Maximum Drawdown**: -68.18%[49][50]

Group 1 - The A-share market has shown a rebound since April 7, with the Wind偏股混合型基金指数 rising over 11% as of June 17, indicating a recovery in active equity products [1][2] - Nearly 70% of active equity funds have turned positive in returns, with 3,079 out of 4,462 funds reporting gains, a significant increase from 10.8% on April 7 [2][3] - The top-performing funds are heavily invested in the pharmaceutical sector, with six out of the top ten funds focusing on this area, driven by Hong Kong innovative drug stocks [3][5] Group 2 - The top fund, 长城医药产业精选A, has achieved a 75.69% return year-to-date, followed closely by 中信建投北交所精选两年定开A and 永赢医药创新智选A with returns of 74% and 70.8% respectively [3] - The performance of the pharmaceutical sector is attributed to the strong showing of Hong Kong innovative drug stocks, which constitute a significant portion of the holdings in these funds [3][6] - Despite recent market corrections in popular sectors like innovative drugs and new consumption, industry experts believe that the long-term value remains intact, with ongoing support from national policies and market demand [5][6] Group 3 - The innovative drug sector has seen a year-to-date increase of 59.18%, while other sectors like humanoid robots and new consumption have also performed well, with gains exceeding 20% [5] - Recent corrections in these sectors are viewed as technical adjustments rather than a sign of a downturn, with analysts suggesting continued investment interest in innovative drugs due to their long-term growth potential [6][7] - The new consumption sector is experiencing a temporary pullback, but the underlying market conditions remain strong, as evidenced by positive consumption data during the recent 618 shopping festival [6][7]

Quantitative Models and Factor Analysis Quantitative Models and Construction Methods Model Name: Hong Kong Stock Market Quantitative Timing Model - **Model Construction Idea**: The model is built around the Hang Seng Index, selecting indicators from five dimensions: fundamentals, liquidity, capital flows, sentiment, and valuation to analyze the factors influencing the rise and fall of the Hong Kong stock market[15]. - **Model Construction Process**: - **Fundamentals**: OECD China Economic Leading Indicator - **Liquidity**: US-Hong Kong interest rate spread, US Dollar Index, US Treasury yields - **Sentiment**: Hang Seng Index options put-call ratio (PCR), Hong Kong stock short-selling turnover ratio - **Capital Flows**: Net foreign capital inflows, Southbound capital - **Valuation**: AH premium index[14] - **Model Evaluation**: The model successfully captured the policy-driven rebound in the Hong Kong stock market from September 23, 2024, to October 10, 2024, and avoided the subsequent downturn by maintaining a predominantly cash position. The model turned bullish again in early 2025 as passive foreign capital accelerated its layout in Hong Kong stocks[15]. Model Backtesting Results - **Hong Kong Stock Market Quantitative Timing Model**: - Successfully captured the policy-driven rebound in the Hong Kong stock market from September 23, 2024, to October 10, 2024[15] - Maintained a predominantly cash position during the subsequent market adjustment, avoiding the downturn[15] - Turned bullish again in early 2025 as passive foreign capital accelerated its layout in Hong Kong stocks[15] Quantitative Factors and Construction Methods Factor Name: OECD China Economic Leading Indicator - **Factor Construction Idea**: This factor is used to gauge the economic outlook of China, which is a significant driver for the Hong Kong stock market[15]. - **Factor Construction Process**: The OECD China Economic Leading Indicator is used directly as a measure of economic activity and outlook[15]. Factor Name: Hang Seng Index Options Put-Call Ratio (PCR) - **Factor Construction Idea**: This factor measures market sentiment by comparing the volume of put options to call options on the Hang Seng Index[15]. - **Factor Construction Process**: The put-call ratio (PCR) is calculated as follows: $$ \text{PCR} = \frac{\text{Volume of Put Options}}{\text{Volume of Call Options}} $$ - **Explanation**: A higher PCR indicates a bearish sentiment, while a lower PCR indicates a bullish sentiment[15]. Factor Name: Net Foreign Capital Inflows - **Factor Construction Idea**: This factor tracks the net amount of foreign capital flowing into the Hong Kong stock market, indicating the level of foreign investor interest and confidence[15]. - **Factor Construction Process**: The net foreign capital inflows are measured by the total amount of foreign capital entering the market minus the total amount exiting the market[15]. Factor Backtesting Results - **OECD China Economic Leading Indicator**: - Successfully indicated the economic outlook and supported the model's timing decisions[15] - **Hang Seng Index Options Put-Call Ratio (PCR)**: - Provided effective signals for market sentiment, aiding in the timing of market entries and exits[15] - **Net Foreign Capital Inflows**: - Accurately reflected foreign investor interest and confidence, contributing to the model's performance[15]

Group 1 - The Hong Kong stock market showed strong performance today, with the Hong Kong Innovative Drug ETF (159567) rising over 2% [1] - The trading volume reached 1.063 billion yuan, an increase of 25.93% compared to the same time yesterday [1] - There has been a net inflow of 46.68 million yuan in financing over the past three days, with a total increase of 47 million units in the fund over the last month [1] Group 2 - The fund supports T+0 trading, which has now been made available globally [1]

1、 中办、国办印发《关于健全资源环境要素市场化配置体系的意见》，深化资源环境要素市场化配 置改革。意见提出，到2027年，碳排放权、用水权交易制度基本完善，排污权交易制度建立健全，节 能市场化机制更加健全，资源环境要素交易市场更加活跃、价格形成机制更加健全，推动资源环境要 素畅通流动、高效配置，充分释放市场潜力，对实现相关资源环境目标的支撑作用有效增强。 2、 记者从中国轻工业联合会了解到，1至4月，规模以上轻工企业实现营业收入7.35万亿元，同比增 长4.9%；实现利润4190.6亿元，同比增长3.8%。在系列扩内需、促消费政策支持下，轻工业经济运行 延续稳中有进态势。 3、 财政部拟第三次续发行2025年超长期特别国债（二期）。本次续发行国债为30年期固定利率附息 债。本次续发行国债竞争性招标面值总额710亿元，不进行甲类成员追加投标。本次续发行国债票面利 率与之前发行的同期国债相同，为1.88%。本次续发行国债的起息日、兑付安排与之前发行的同期国 债相同。 今日导读 4、5月28日，深圳市住房和建设局网站发布《深圳市配售型保障性住房管理办法（征求意见稿）》 《深圳市保障性住房规划建设管理办法（修订征求 ...

Group 1 - The core viewpoint of the articles highlights a strong performance in the Hong Kong pharmaceutical and biotechnology sector, with the Hang Seng Healthcare Index rising by 1.69% and reaching over 2.2% at one point [1] - The Hang Seng Medical Index ETF (159557) saw an increase of 1.34% with a trading volume exceeding 11 million, indicating active trading [1] - Notable stock performances include Green Leaf Pharmaceutical rising over 10%, and several other companies like Haijia Medical and Kangzhe Pharmaceutical increasing by over 8% [1] Group 2 - The issuance of 225 million shares by Hengrui Medicine in Hong Kong led to a stock price increase of over 33% during trading [1] - The current market environment suggests a focus on innovative drugs in Hong Kong, driven by the potential for excess returns as companies establish global competitive advantages [2] - The global competitive advantage of Chinese innovative drugs is becoming more apparent, with significant growth in License-out transactions in overseas markets [2] Group 3 - Recent policy and regulatory changes are favorable for the sector, including optimization of centralized procurement rules and increased support for innovative drugs [2] - Financially, leading Hong Kong innovative pharmaceutical companies are benefiting from increased License-out volumes, resulting in steady revenue and profit growth [2] - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, indicating a favorable investment environment [2]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]